EXHIBIT 10.31
[*]= Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
of 1934, as amended.
AMENDMENT II: SPECIFIC RESEARCH AGREEMENT
Whereas Yissum Research and Development Company of the Hebrew University of
Jerusalem ("Yissum") and SEQUUS Pharmaceuticals, Inc. ("SEQUUS"; formerly
Liposome Technology, Inc.) are parties to a MASTER RESEARCH SERVICES AND LICENSE
AGREEMENT ("Master Agreement") entered into on or about January 1, 1995; and
Whereas the parties desire to continue a research program under the Master
Agreement;
Therefore, Yissum and SEQUUS agree as follows:
In accordance with article II of the Master Agreement, the parties agree to
amend the Master Agreement as follows:
1.1 Research Program. The Research Program is described in Appendix A:
"Proposal for EXM Studies for 1.7.96.-30.6.97.
1.2 Research Period. The Research Period shall be from July 1, 1996 through
June 30, 1997.
1.3 Research Fee. The Research Fee shall be [*].
1.4 Budget and Payment Schedule. The Budget and Payment Schedule shall be as
follows:
Upon signing: [*]
Upon receipt and approval of interim report: [*]
Upon receipt and approval of final report: [*]
1.5 Schedule of Deliverables
Interim report due: February 1997
Final report due: July 1997
IN WITNESS WHEREOF, the parties hereto have cause this Specific Research
Agreement to be duly executed.
SEQUUS PHARMACEUTICALS, INC. YISSUM RESEARCH DEVELOPMENT COMPANY
[*] =CONFIDENTIAL TREATMENT REQUESTED
1.
By: /s/ Xxxxxx X. Xxxxxxx By: /s/ Xxxxxx Xxx
-------------------------- ---------------------------------
Title: Sr V.P., R+D Title: Deputy Managing Director
----------------------- ------------------------------
Date: 9/11/96 Date: October 10th 1996
------------------------ -------------------------------
[*] =CONFIDENTIAL TREATMENT REQUESTED
2.